Gu Jun, Hu Wei, Liu Xu
Department of Cardiology, Shanghai Minhang District Central Hospital, Fudan University, Shanghai, China (mainland).
Department of Cardiology, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China (mainland).
Med Sci Monit Basic Res. 2014 Oct 8;20:153-60. doi: 10.12659/MSMBR.892450.
It has been demonstrated that atrial electrical remodeling contributes toward atrial fibrillation (AF) maintenance, and that angiotensin II (AngII) is involved in the pathogenesis of atrial electrical remodeling. Peroxisome proliferator activated receptor-γ (PPAR-γ) agonists have been shown to inhibit atrial electrical remodeling, but the underlying mechanisms are poorly understood. In the present study we investigated the regulating effects of PPAR-g agonist on AngII-induced potassium channel remodeling in atrial myocytes.
MATERIAL/METHODS: Whole-cell patch-clamp technique was used to record transient outward potassium current (Ito), ultra-rapid delayed rectifier potassium (Ikur), and inward rectifier potassium current (Ik1). Real-time PCR was used to assess potassium channel subunit mRNA expression.
Compared with the control group, AngII reduced Ito and Ikur current density as well as amplified Ik1 current density, which were partially prevented by pioglitazone. Furthermore, pioglitazone alleviated the downregulation of Ito subunit (Kv 4.2) and Ikur subunit (Kv 1.5), as well as the upregulation of Ik1 subunit (Kir 2.1 and Kir 2.2) mRNA expression stimulated by AngII.
These results suggest that pioglitazone exhibits a beneficial effect on AngII-induced potassium channel remodeling. PPAR-γ agonists may be potentially effective up-stream therapies for AF.
已有研究表明,心房电重构有助于心房颤动(AF)的维持,且血管紧张素II(AngII)参与心房电重构的发病机制。过氧化物酶体增殖物激活受体γ(PPAR-γ)激动剂已被证明可抑制心房电重构,但其潜在机制尚不清楚。在本研究中,我们研究了PPAR-γ激动剂对AngII诱导的心房肌细胞钾通道重构的调节作用。
材料/方法:采用全细胞膜片钳技术记录瞬时外向钾电流(Ito)、超快速延迟整流钾电流(Ikur)和内向整流钾电流(Ik1)。采用实时PCR评估钾通道亚基mRNA表达。
与对照组相比,AngII降低了Ito和Ikur电流密度,并增大了Ik1电流密度,而吡格列酮可部分阻止这种变化。此外,吡格列酮减轻了AngII刺激引起的Ito亚基(Kv 4.2)和Ikur亚基(Kv 1.5)的下调,以及Ik1亚基(Kir 2.1和Kir 2.2)mRNA表达的上调。
这些结果表明,吡格列酮对AngII诱导的钾通道重构具有有益作用。PPAR-γ激动剂可能是潜在有效的房颤上游治疗药物。